Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy

被引：5
作者：
Chenam A. [1 ]
Parihar J.S. [1 ]
Ruel N. [2 ]
Pal S. [3 ]
Avila Y. [1 ]
Yamzon J. [1 ]
Lau C. [1 ]
Yuh B. [1 ]
机构：
[1] Division of Urology and Urologic Oncology, Department of Surgery, City of Hope National Medical Center, 1500 E. Duarte Rd, MOB L002H, Duarte, 91010, CA
[2] Department of Biostatistics, City of Hope National Medical Center, Duarte, CA
[3] Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA
来源：
Journal of Robotic Surgery | 2018年 / 12卷 / 3期
关键词：
Adjuvant; Extended lymph node dissection; Lymph node positive; Prostate cancer; Robotic prostatectomy; Salvage;
D O I：
10.1007/s11701-017-0751-8
中图分类号：
学科分类号：
摘要：
Optimal management of node-positive prostate cancer patients after prostatectomy remains a challenge. We evaluated clinically localized patients who demonstrated node positivity and identified predictors for secondary treatment. From 2010 to 2015, clinically localized prostate cancer patients who underwent robot prostatectomy with extended lymphadenectomy and node-positive disease on pathologic analysis were identified. Clinical N1, M1 or salvage cases were excluded. Patients were stratified based on secondary treatments. Kaplan–Meier method was used to determine the time to biochemical and metastatic recurrence. Multivariate logistic regression was used to identify predictors for additional treatment. 145 patients (45 no additional therapy, 47 adjuvant, 53 salvage) had a median follow-up of 31.2 months. Salvage patients had higher median pre-operative prostate-specific antigen (10.8 vs. 9.7 vs. 8.2, p = 0.1), higher percentage of pathologic Gleason ≥8 (50.9 vs. 38.3% and 22.2%, p < 0.01), and higher median-positive nodes (3 vs. 1 and 1, p < 0.0001) compared to adjuvant and no treatment groups, respectively. Pathologic Gleason ≥8 (OR = 3.5, p = 0.007) and positive nodes ≥2 (OR = 3.3, p = 0.006) were associated with additional therapy. In the no treatment group, two-year estimated BCRFS was 74.3%. Two-year metastatic recurrence-free rates for no treatment, adjuvant and salvage groups were 100, 87.5, and 80.9%, respectively (p = 0.01). Observation is a viable alternative for low metastatic burden patients. In the largest series of node-positive patients from robotic prostatectomy and extended lymphadenectomy, those with pathologic Gleason ≥8 and positive lymph nodes ≥2 were more likely to receive additional treatment. © 2017, Springer-Verlag London Ltd.
引用
收藏
页码：425 / 431
页数：6
相关论文
共 16 条
  • [1] Eggener S.E., Scardino P.T., Walsh P.C., Et al., Predicting 15-year prostate cancer specific mortality after radical prostatectomy, J Urol, 61, pp. 212-236, (2011)
  • [2] Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Et al., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013, Eur Urol, 65, pp. 124-137, (2014)
  • [3] Abdollah F., Suardi N., Gallina A., Et al., Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center, Ann Oncol, 24, pp. 1459-1466, (2013)
  • [4] Abdollah F., Sun M., Thuret R., Et al., Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer, Eur Urol, 58, pp. 882-892, (2010)
  • [5] Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with positive prostate cancer, N Engl J Med, 341, pp. 1781-1788, (1999)
  • [6] Zwergel U., Lehmann J., Wullich B., Schreier U., Remberger K., Zwergel T., Et al., Lymph node positive prostate cancer: long-term survival data after radical prostatectomy, J Urol, 171, pp. 1128-1131, (2004)
  • [7] Boorjian S.A., Thompson R.H., Siddiqui S., Et al., Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era, J Urol, 178, pp. 864-870, (2007)
  • [8] Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., Studer U.E., Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy, Eur Urol, 54, 2, pp. 344-352, (2008)
  • [9] Yuh B.E., Ruel N.H., Mejia R., Wilson C.M., Wilson T.G., Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer, Eur Urol, 61, pp. 1009-1010, (2012)
  • [10] Carlsson S.V., Tafe L.J., Chade D.C., Sjoberg D.D., Passoni N., Shariat S.F., Et al., Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer, J Urol, 189, pp. 1314-1319, (2013)
12